CD68 and gastric cancer: We first explored the clinical value of the CD68 (TAMs marker) in gastric cancer tissues from patients with gastric cancer who had undergone 5-FU-based neoadjuvant chemotherapy and elucidated the correlation between the infiltration of TAMs and the resistance of gastric cancer to chemotherapy.